00:33 , Apr 5, 2016 |  BC Extra  |  Financial News

Human Longevity raises $220M series B

Human Longevity Inc. (San Diego, Calif.) raised $220 million in a series B financing that included Illumina Inc. (NASDAQ:ILMN), Celgene Corp. (NASDAQ:CELG) and GE Ventures. Human Longevity said its series A investors also participated. J....
07:00 , Mar 10, 2014 |  BioCentury  |  Finance

Venter's fellow travelers

Venter's fellow travelers J. Craig Venter's vow to build the world's largest human sequencing operation has drawn at least two previous investors to his latest genomics play. Venter launched Human Longevity Inc. last week with...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Haemonetics, Hemerus Medical deal

Blood management solutions company Haemonetics completed its acquisition of Hemerus for $24 million in cash. Haemonetics will pay an additional $3 million in cash upon FDA approval of Hemerus' SOLX whole blood collection system for...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

RenaGel phosphate binder data

GELX announced positive results of a second Phase III trial of RenaGel to control elevated serum phosphorus levels in chronic kidney failure patients. The study, which included 82 dialysis patients with chronic kidney failure, began...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

Suprep regulatory update

Braintree and partner Ipsen Group (Euronext:IPN; Pink:IPSEY, Boulogne-Billancourt, France) said Eziclen/Izinova was approved under the EU's decentralized procedure for bowel cleansing prior to any procedure requiring a clean bowel. France acted as the reference member...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Haemonetics, Hemerus Medical, Pall deal

Blood management solutions company Haemonetics announced two deals that it says will accelerate its entry into the whole blood collection market. The company will acquire Hemerus for up to $27 million in cash based on...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Company News

Biomet, Cytosol Laboratories Inc. deal

Biomet Inc. , Warsaw, Ind.   Cytosol Laboratories Inc. , Braintree, Mass.   Business: Hematology   Biomet will acquire substantially all the assets of Cytosol for an undisclosed sum. Cytosol has three products approved in...
07:00 , Oct 19, 2009 |  BC Week In Review  |  Company News

Braintree, Ipsen deal

Ipsen received exclusive rights to market Braintree's BLI-800 in the EU, Commonwealth of Independent States, China, other Asian countries and parts of North Africa. The compound with an undisclosed mechanism of action has completed Phase...
07:00 , Oct 22, 2007 |  BioCentury  |  Regulation

Sales of phosphate binders

Sales of phosphate binders Sales of phosphate bindersGenzyme's Renagel sevelamer hydrochloride dominates the market for phosphate binders, with $515.1 million in 2006 revenues. Sales of Shire's Fosrenol lanthanum carbonate were $45 million in 2006, and...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Company News

Braintree, National Institute for Agricultural Research deal

The institute granted Braintree worldwide development and commercialization rights to BLI-6000, a chemoprotectant. The company expects to file an IND for BLI-6000 to treat colorectal cancer this quarter. Braintree Laboratories Inc. , Braintree, Mass.  ...